Salix Pharmaceuticals Ltd. (SLXP)
-NasdaqGS 71.82 
1.06(1.50%) 10:42AM EDT - Nasdaq Real Time Price
| Prev Close: | 70.76 |
|---|
| Open: | 70.57 |
|---|
| Bid: | 72.29 x 100 |
|---|
| Ask: | 72.34 x 200 |
|---|
| 1y Target Est: | 75.13 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 7-Nov-13 |
|---|
| Day's Range: | 70.41 - 73.94 |
|---|
| 52wk Range: | 37.52 - 75.87 |
|---|
| Volume: | 412,580 |
|---|
| Avg Vol (3m): | 784,466 |
|---|
| Market Cap: | 4.43B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Healthcare Stocks Up as Obamacare Takes HoldWyatt Investment Research(Tue, Oct 1)
- InPlay: Salix Pharma and Progenics (PGNX) announce FDA Advisory Committee scheduled to review RELISTOR sNDA for opioid-induced constipation in patients with chronic painBriefing.com(Tue, Oct 1)
- Salix and Progenics Announce FDA Advisory Committee Scheduled to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic PainBusiness Wire(Tue, Oct 1)
- Interesting SLXP Put And Call For November 16that Forbes(Fri, Sep 27)
- Salix initiated with a Neutral at Goldmantheflyonthewall.com(Tue, Sep 17)
- Dr. Andrew Baum, Group Head of Health Care Research at Citigroup, Interviews with The Wall Street Transcript: Big Pharma Uses Size for Advantageous Capital-Allocation PracticesWall Street Transcript(Mon, Sep 16)
- James S.J. Manuso, the Chairman and CEO of Astex Pharmaceuticals, Inc. (ASTX), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Sep 13)
- SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, Sep 10)
- Salix upgraded to Outperform from Market Perform at Leerinkat theflyonthewall.com(Mon, Sep 9)
- Why Oak Ridge Is Bullish On These Small Capsat Seeking Alpha(Wed, Sep 4)
- Salix Pharmaceuticals Previews PAINWeek® PresentationBusiness Wire(Wed, Sep 4)
- COLUMN-Use convertibles to straddle stock and bond marketsat Reuters(Tue, Sep 3)
- 3 Humongous Health-Care Stocks This Weekat Motley Fool(Sat, Aug 31)
- Salix Pharmaceuticals: Why You Shouldn't Be Dumping This Stock?at Seeking Alpha(Thu, Aug 29)
- Progenics Pharmaceuticals - Alive Again With Institutional Backing?at Seeking Alpha(Mon, Aug 26)
Key Statistics
| Forward P/E (1 yr): | 16.90 |
|---|
| P/S (ttm): | 5.31 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.24 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.86 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 0.98 |
|---|
Business Summary
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States.
View More